Business
PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110
PRF-110 promoted normal wound healing and prevented scar formation following surgical procedures Company reaffirms it is on track to report top-line results
About this update from Prf Technologies Ltd.
[{"type":"text","content":"PRF-110 promoted normal wound healing and prevented scar formation following surgical procedures Company reaffirms it is on track to report top-line results from the Phase 3 trial in the second half of 2024 TEL AVIV, Israel, Aug. 05, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (\"PainReform\" or the \"Company\"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announces positive wound healing data from its human clinical trials investigating the efficacy of PRF-110, the Company’s lead asset designed to provide extended, non-opiate, post-surgical pain relief. Building on extensive preclinical research, PainReform previously conducted wound healing studies in animal models which demonstrated that PRF-110 allows for normal wound healing of surgical incisions comparable to both Naropin® (ropivacaine) and saline. Importantly, these studies showed no adverse histological or radiologic effects on soft or bony tissues. The recent human clinical trials included patients undergoing both hard tissue (bunionectomy) and soft tissue (hernia) surgeries. Results from these trials indicated no abnormalities in wound healing or scar formation among patients treated with PRF-110. Wound healing in all patients was complete and consistent with outcomes expected from surgeries without PRF-110. PRF-110's formulation includes approximately 55% lecithin, which forms liposome-like structures upon contact with body fluids. This feature is particularly noteworthy as existing literature suggests that lecithin liposomes enhance wound healing through in vitro antioxidant activity and in vivo wound-healing models (J Comp Eff Res. 2019 Nov;8(15):1343). The potential beneficial effects of PRF-110 on the wound healing process are further supported by these in vitro, in vivo, and human studies. Ehud Geller, Chairman and interim Chief Executive Officer of PainReform, commented, \"We are very encouraged by the favorable wound healing data from our human clinical trials for PRF-110. These findings support the potential of PRF-110 not only to provide effective pain relief but also to promote normal wound healing and prevent scar formation. We believe PRF-110 could significantly enhance post-surgical recovery and patient outcomes.\" PainReform continues to advance the development of PRF-110 and is ...